AEs and assessment of tumor response
neurotoxicity, Neurologic Toxicity, CRS, Cancer
ADVERSE EVENT, CYTOKINE RELEASE SYNDROME, CANCER
AEs were assessed and graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 on a five-point scale (grade 1–5). CRS and neurotoxicity were evaluated using the ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells